Teresa Brophy Bair Sells 2,615 Shares of Kura Oncology, Inc. (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURAGet Free Report) insider Teresa Brophy Bair sold 2,615 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $22.15, for a total transaction of $57,922.25. Following the transaction, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,527,884.85. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $22.11 on Wednesday. The business has a fifty day moving average of $20.55 and a 200-day moving average of $17.16. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.67 and a current ratio of 16.67. Kura Oncology, Inc. has a twelve month low of $7.41 and a twelve month high of $24.17. The firm has a market cap of $1.68 billion, a PE ratio of -10.19 and a beta of 0.89.

Kura Oncology (NASDAQ:KURAGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same quarter in the previous year, the business posted ($0.50) EPS. The business’s revenue was up .0% compared to the same quarter last year. On average, equities research analysts predict that Kura Oncology, Inc. will post -2.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on KURA shares. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, May 14th. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Thursday, May 16th. Finally, Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.94.

Read Our Latest Research Report on KURA

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Deerfield Management Company L.P. Series C raised its position in shares of Kura Oncology by 35.1% during the third quarter. Deerfield Management Company L.P. Series C now owns 4,374,044 shares of the company’s stock worth $39,891,000 after acquiring an additional 1,136,044 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after purchasing an additional 870,000 shares during the last quarter. BVF Inc. IL lifted its position in Kura Oncology by 9.5% during the 4th quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock valued at $106,027,000 after purchasing an additional 642,245 shares during the period. Affinity Asset Advisors LLC boosted its stake in shares of Kura Oncology by 281.4% in the 1st quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after purchasing an additional 538,957 shares during the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Kura Oncology during the 4th quarter worth approximately $6,695,000.

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

See Also

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.